{"id":"NCT01067339","sponsor":"Mayo Clinic","briefTitle":"Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary Atherosclerosis in Humans","officialTitle":"Lp-PLA2, Progenitor Cells and Coronary Atherosclerosis in Humans AIM III","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-02-04","primaryCompletion":"2015-11","completion":"2015-11","firstPosted":"2010-02-11","resultsPosted":"2017-03-15","lastUpdate":"2017-04-18"},"enrollment":70,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Endothelial Dysfunction"],"interventions":[{"type":"DRUG","name":"darapladib","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Darapladib","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"AIM III is a prospective, randomized, double-blinded, placebo controlled trial. The study is directly connected to IRB 08-008161 as a specific aim of the National Institute of Health (NIH) grant. Participants may either consent to and qualify for AIM I and AIM II (IRB 08-008161) or have a cardiac catheterization with acetylcholine testing in the Cardiac Catheterization Laboratory at Mayo Clinic in Rochester, Minnesota to be considered for this study.","primaryOutcome":{"measure":"Percentage Change in Coronary Artery Diameter","timeFrame":"baseline, six months","effectByArm":[{"arm":"Darapladib","deltaMin":3,"sd":null},{"arm":"Placebo","deltaMin":3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["29306475"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":31},"commonTop":["Chest discomfort/angina","Sinus Infection","Influenza","Vaginal yeast infection","Chest pain"]}}